These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6489890)

  • 21. Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis.
    Levine JP
    Curr Womens Health Rep; 2003 Jun; 3(3):181-6. PubMed ID: 12734027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perimenopausal knowledge of mid-life women in northern Taiwan.
    Tsao LI; Chang WY; Hung LL; Chang SH; Chou PC
    J Clin Nurs; 2004 Jul; 13(5):627-35. PubMed ID: 15189416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of progestins in the menopausal patient: dosage and duration.
    Gambrell RD
    J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen use and postmenopausal women: a basis for informed decisions. NIH Consensus Development.
    Gastel B; Cornoni-Huntley J; Brody JA
    J Fam Pract; 1980 Nov; 11(6):851-60. PubMed ID: 7005387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hormone therapy and the risk of cancer in the climacteric].
    Kuhl H; Taubert HD
    Gynakologe; 1986 Dec; 19(4):259-65. PubMed ID: 3817599
    [No Abstract]   [Full Text] [Related]  

  • 26. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
    Andersson K; Stadberg E; Mattsson LA; Rybo G; Samsioe G
    Int J Fertil Menopausal Stud; 1996; 41(5):476-83. PubMed ID: 8934257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances and risks in estrogen therapy in the perimenopause].
    Lauritzen C
    Wien Klin Wochenschr; 1983 Oct; 95(20):748-51. PubMed ID: 6659519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormone replacement therapy. Indications, benefits and risk.
    Davis S
    Aust Fam Physician; 1999 May; 28(5):437-45. PubMed ID: 10376367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial.
    Franke HR; Snaaijer FF; Houben PW; van der Mooren MJ
    Gynecol Endocrinol; 2006 Dec; 22(12):692-7. PubMed ID: 17162712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis.
    Gorsky RD; Koplan JP; Peterson HB; Thacker SB
    Obstet Gynecol; 1994 Feb; 83(2):161-6. PubMed ID: 8290175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
    Savoca S; D'Agosta S; Lombardo G
    Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic concepts in the treatment of postmenopausal osteoporosis].
    Leidig-Bruckner G; Ziegler R
    Ther Umsch; 1994 Nov; 51(11):737-47. PubMed ID: 7839332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Menopause and hormone replacement therapy].
    Tóth KS
    Orv Hetil; 2000 Mar; 141(11):547-56. PubMed ID: 10741167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Links between hormone replacement therapy and neoplasia.
    Hulka BS
    Fertil Steril; 1994 Dec; 62(6 Suppl 2):168S-175S. PubMed ID: 7958013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal replacement therapy: benefits, risks, doses.
    Huppert LC
    Med Clin North Am; 1987 Jan; 71(1):23-39. PubMed ID: 3543541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Climacteric symptoms and estrogen replacement therapy in women with endometrial carcinoma.
    Pettersson B; Adami HO; Persson I; Bergström R; Lindgren A; Johansson ED
    Acta Obstet Gynecol Scand; 1986; 65(1):81-7. PubMed ID: 3716786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Menopausal symptoms in breast carcinoma patients. Is effective treatment possible?].
    Rauthe G
    Fortschr Med; 1996 Feb; 114(5):46-8. PubMed ID: 8867475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.